MYGNのROE（自己資本利益率）は？

MYRIAD GENETICS INCのROEは-118.52%です。

MYGNの配当利回りは？

MYRIAD GENETICS INCの配当利回りは0.00%です。

MYGNの品質スコア（Quality Score）は？

当社のAIはMYGNの総合財務品質を100点中31点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。

MYGNは今が買い時ですか？

当社AIのタイミングスコアは100点中56点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。

MYGNはどのセクターに属しますか？

MYRIAD GENETICS INCはHealthcare >> Diagnostics & Researchセクターに分類されます（NASDAQ市場）

MYGN (NASDAQ) 株価分析 | MYRIAD GENETICS INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

MYGN AI Analysis Summary

Our AI summary for MYGN: MYRIAD GENETICS INC (NASDAQ), Healthcare >> Diagnostics & Research sector. The stock currently trades at a P/E of 0.00, ROE of -118.52%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 56/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

MYGN

MYRIAD GENETICS INC

US:NASDAQ STOCK Healthcare >> Diagnostics & Research News 80

USD 2.86

-2.51 (-46.74%) Day Change

Watchlist Portfolio Compare Chart

0.38

D/E

-118.5%

ROE

-59.4%

ROA

0.00%

Div Yield

MYRIAD GENETICS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 2.86 Price -2.51 (-46.74%) Day Change	NEWS SCORE: 80

MYGN, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そしてテクニカルスコアは ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...

Deepscope 分析

47%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	80
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	2.86
PBV / Sector	1.50 / -29.69 GOOD
Earning Per Share	-2.26

PE / Sector	N/A / 48.18
PEG or PE/Growth / Sector	N/A / 1.64
Average 1M Daily Value	7.55 M
Average 1W Daily Value	14.58 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

ポイントになる統計

60%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-48.24 / 13.01
NPM Average (%) / Sector	-31.86 / 7.90
NPM Change Average (%) / Sector	63.98 / -6.69 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-59.36 / 11.73
ROA Average (%) / Sector	-31.17 / -87.10
ROA Change Average (%) / Sector	108.09 / 167.77 GREAT
ROE (%) / Sector	-118.52 / -89.83
ROE Average (%) / Sector	-56.47 / -2.30
ROE Change Average (%) / Sector	146.68 / -47.20 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

配当

Dividend (%) / Sector	N/A / 0.18
Dividend Average (%) / Sector	N/A / 1.19
Dividend Change Average (%) / Sector	N/A / 4.52

登録情報

Analyze Date	2026-08-01 08:00:12
Symbol	MYGN
Name	MYRIAD GENETICS INC
Sector	Healthcare >> Diagnostics & Research
Market	NASDAQ
Listed Shares	94.45 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	507.19 / 38,081.42

ニュース

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 322 North 2200 West, Salt Lake City, UT, United States, 84116

Phone: 801 584 3600

Website: https://www.myriad.com

Employees: 2,700

Sector: Healthcare >> Diagnostics & Research

Description: Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.